Launch week offerEnds in00h00m00s
annual Promonthly Pro
Thomas Proft
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Professor Thomas Proft is a faculty member at The University of Auckland in New Zealand. His research focuses on the pathogenesis of Group A Streptococcus, including its virulence factors and implications for vaccine development. Recent publications highlight his work on the immune evasion strategies of pathogenic Gram-positive bacteria and novel mechanisms to enhance oral drug delivery through PEGylated niosomes.
Recent Grants
Grant: Open
Complement evasion factor (CEF) - a novel candidate for the development of a vaccine against Group A Streptococcus.
Open Date: 2024-01-01
Close Date: 2027-01-01
Grant: Close
Investigations into a novel putative immune evasion factor from Group A Streptococcus
Open Date: 2018-11-01
Close Date: 2020-11-01
Grant: Close
GASPEL - a novel mucosal vaccine against Group A Streptococcus?
Open Date: 2018-10-01
Close Date: 2020-09-01
Grant: Close
PilVax a novel peptide delivery strategy for the development of vaccines against TB
Open Date: 2017-03-01
Close Date: 2020-02-01
Grant: Close
PilVax: a novel peptide delivery strategy for the development of vaccines
Open Date: 2017-01-01
Close Date: 2020-01-01
Articles (16)
Year:
2026
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
The human pathogen Streptococcus pyogenes , or Group A Streptococcus (GAS), is associated with a variety of diseases ranging from mild skin and soft tissue infections to invasive diseases and immune sequelae such as rheumatic heart disease. We have recently reported that one of the virulence factors of this pathogen, the pilus, has inflammatory properties and strongly stimulates the innate immune system. Here we used a range of nonpathogenic Lactococcus lactis gain‐of‐function mutants, each expressing one of the major pilus types of GAS, to compare the immune responses generated by various types of fully assembled pili. In vitro assays indicated variability in the inflammatory response induced by different pili, with the fibronectin‐binding, collagen‐binding, T antigen (FCT)‐1‐type pilus from GAS serotype M6/T6 inducing significantly stronger cytokine secretion than other pili. Furthermore, we established that the same trend of pili‐mediated immune response could be modeled in Galleria mellonella larvae, which possess a similar innate immune system to vertebrates. Counterintuitively, across the panel of pili types examined in this study, we observed a negative correlation between the intensity of the immune response demonstrated in our experiments and the disease severity observed clinically in the GAS strains associated with each pilus type. This observation suggests that pili‐mediated inflammation is more likely to promote bacterial clearance instead of causing disruptive damages that intensify pathogenesis. This also indicates that pili may not be the main contributor to the inflammatory symptoms seen in GAS diseases. Rather, the immune‐potentiating properties of the pilus components could potentially be exploited as a vaccine adjuvant.
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2020
Year:
2020
Year:
2020
Collaborators (9)
Joanna Kirman
Associate Professor
University of Otago
Jacelyn Mei San Loh
-
Yi Tian Ting
MONASH UNIVERSITY
Adrina Hema Jethanand-Khemlani
University of Auckland
Darren Svirskis
University of Auckland
Catherine Jia‐Yun Tsai
Senior Research Fellow
University of Auckland
Mengyang Liu
University of Auckland
Julie Bennett
Associate Professor
University of Otago
Jingyuan Wen
Professor
University of Auckland
Make your next move.
Prepare your application
Review drafts before you send them.